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1. Introduction
  Studies in past decades have shown the significant role of micro 
RNAs (miRNA) in hepatocellular cancinoma (HCC)[1,2]. The 
miRNA family plays an important role in the cell proliferation, 
differentiation, apoptosis and necrosis, etc and its dysfunction 
contributes to the tumor onset and progression[3-5]. It is reported 
that more than 50% of miRNA genes are located in fragile sites or 
cancer-associated genomic regions[6]. Thus, the alteration in the 
miRNA expression will activate the abnormal expression of cancer 
genes, influencing the progression and metastasis etc. of cancers[7]. 
Many miRNAs are involved in the hepatocarcinogenesis, including 
miR-214. The general down-regulation of miR-214 gene in 
HCC[8,9] can stimulate the development of this cancer by targeting 
on its downstream proteins[9]. To date, a number of studies on the 
relationship between miR-214 expression and HCC have been 
reported at home and abroad, while there is scarce information on its 
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mechanism in HCC development. In this study, the human hepatoma 
cells were used as the research object and their responses to miR-214 
treatment were evaluated in the cell growth, proliferation, colony 
forming ability and cell cycles, as well as 毬-catenin pathway. The 
present study provided further information on the mechanism of 
miR-214 in HCC and may be a scientific reference for HCC therapy 
through modulating miRNA expression.
2. Materials and methods
2.1. Materials
  Cell lines: Human hepatoma (HepG2), normal hepatic cells and 
293T cells were obtained from the Institute of Biochemistry and Cell 
Biology of Chinese Academy of Sciences. The Escherichia coli (E. 
coli) strains (DH5毩) were produced in our laboratory.
  Reagents: hsa-miR-214 plasmid (Beijing OriGene Techologies 
Co., Ltd, China); RPMI-1640 and DMEM medium (Gibco, USA); 
fetal bovine serum and propidium iodide (PI) (Beijing solarbio 
science & technology co., ltd., China); methyl thiazolyl tetrazolium 
(MTT) (System Biosciences, USA); pLenR-GPH and Lv-control 
vectors and Lentivirus plasmid (Shanghai Innovation Biotechnology 
Co.,Ltd., China); Lipofectamine2000 and TRIzol commercial kits 
(Invitrogen, USA); Opti-MEM (Hyclone, USA); endonucleases 
including BamH I, EcoR I, Kpn I and Xba I (NEB, USA); Taqman 
microRNA RT kit, Taqman miRNA Assays, Taqman Universal PCR 
Master Mix (Appliedbiosysrems, USA); T4DNA ligase (Thermo, 
USA); Agarose, PCR kit, BAC kit (Sangon Biotech (Shanghai) 
Co.,Ltd., China); Antibody and second antibody of 毬-catenin, 
Cyclin D1, c-Myc, TCF-1 and 毬-actin (Beijing Chinese fir golden 
bridge biotechnology co., Ltd., China).
  Instruments: Synergy 2 multimode reader (Biotek, USA); 
SHELLAB CO2 incubator (SHELLAB, USA); Stratedigmflow 
cytometry (Stratedigm, USA); Biometra gradient PCR amplifier 
(Biometra, Germany); DYY-2C electrophoresis apparatus (Beijing 
Liuyi Instrument Plant, China); BioSpectrum- UVP Gel Imaging 
System (UVP, USA).
2.2. Preparation of miR-214 cell lines
  The pre-miR-214 primer was designed using the software Primer 
5.0. After PCR amplification, the AGE and following recovery and 
purification of PCR products were conducted using SanPrep gel 
extraction kit (Sangon Biotech (Shanghai) Co.,Ltd., China). The 
obtained target gene and pCDH-CMV-MCS-EF1-copGFP lentiviral 
vector were treated with double enzymes restriction in presence 
of EcoR I and BamH I according to protocols of commercial kits 
(Axygen) respectively. Target genes were cloned into the vector 
according to the manufacture’s protocol. 
  The miR-214 lentiviral vector was prepared with the connection 
product and E. coli strain DH5 毩. The final bacterial suspensions 
transfected with miR-214 was used for PCR amplification and 
followed by enzyme digestion and sequencing if bacterial colonies 
were determined to be positive. The plasmids were extracted from 
the bacterial suspensions. The packaged lentiviral vector was named 
Lv-miR-214, using the empty lentiviral vector as a control (Lv-
control).
  Exponential 293T cells were cultured in serum-free medium in 
a CO2 incubator (37 曟, 5% CO2). After a fusion of 90%-95%, 
cells were transfected with Lv-miR-214 or Lv-control using 
Lipofectamine 2000 Transfection Kit (Invitrogen) and further 
cultured in medium with 10% FBS. HepG2 cells were infected with 
the packaged lentiviruses to obtain the HepG2 transfectant stably 
expressing miR-214 (Lv-miR-214-HepG2) and its control Lv-
control-HepG2.
  All reaction systems and conditions were listed as following:
  PCR system (50 毺L): 10暳buffer 5 毺L, sense (10 毺M) and anti-
sense primers (10 毺M) 1 毺L respectively, has-miR-214 plasmid 
(100 ng/毺L) 1 毺L, dNTPs (10 mM) 0.5 毺L, Pfu enzymes1 毺L, 
ddH2O 40.5 毺L.
  PCR amplifying conditions: 95 曟 2 min; 95 曟 20 s, 60 曟 20 s, 
72 曟 15 s (30 cycles); 72 曟 3 min.
  Enzyme digestion system (20 毺L): 10暳buffer 2 毺L, 10暳
BSA   2 毺L, EcoR I (10 U/毺L) and BamH I (10 U/毺L) 1 毺L 
respectively, vectors or purified PCR product (500 ng/毺L) 10 毺L, 
ddH2O 4 毺L, 37 曟 2 h.
  Connection system (10 毺L): vectors 2 毺L, target genes 6 毺L, 10
暳T4 buffer 1 毺L, T4DNA ligase 1 毺L, 22 曟 1 h.
2.3. Cell growth
  Exponential Lv-miR-214-HepG2 (experiment group), Lv-control-
HepG2 (negative control group) and HepG2 (blank control group) 
cells at the concentration of 4暳10
4 cells/mL were inoculated into 
96-well plate and culture at  37 曟, 5% CO2 and humidity of 60% for 
5 d. Each group was triplicated.  Over culture period, cells in each 
group were counted every 24 h.
2.4. Cell proliferation
  Exponential Lv-miR-214-HepG2 and Lv-control-HepG2 cells were 
cultured at 37 曟 and 5% CO2 for 24 h. Then cells were cultured 
at 2暳10
4 cells/ml in a fresh culture medium. Each group was 
quintuplicated. During the culture period of 4 d, inhibition of cell 
proliferation was determined at 0, 24, 48, 72 and 96 h by the MTT 
method. Briefly, 20 毺L MTT (5 g/L) was added into each well and 
the medium was replaced with 150 毺L DMSO. The absorbance was 
read at 570 nm after a continuous shake of 10 min. The inhibitory 
rate (%) = (ODcontrol - ODexperiment)/ ODcontrol暳100
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2.5. Cell colony forming ability 
  Lv-miR-214-HepG2 and Lv-control-HepG2 of 2暳10
2 cells were 
respectively inoculated into soft agar whose diameter was 60 mm 
and concentration was 4 g/L at the top and 5 g/L at the bottom. 
After two weeks of culture at 37 曟 and 5% CO2, the colonies were 
observed using an inverted phase contrast microscope. The colony 
diameter >50 毺m was used as standard to calculate the colony 
forming ability according to the formula: colony forming ability (%) 
= colony number /seeded cells暳100 with.
2.6. Cell cycles
  Exponential Lv-miR-214-HepG2 and Lv-control-HepG2 cells were 
digested with trypsin and rinsed by PBS. Cells were fixed for 24 h at 
4 曟 after an addition of ice-cold ethanol (75%) and then rinsed by 
PBS again. RNA enzyme A was added to stop the catalytic reaction 
and removed by PBS. Following the addition of PI, samples were 
placed in the darkness for 30 min to form color. Cell cycles were 
analyzed with a flow cytometry.
2.7. 毬-catenin and downstream proteins
  The mRNA level of 毬-catenin was determined with the RT-
PCR method. A proper quantity of cell samples was mixed with 
Trizol reagent. Total RNA was extracted using a commercial kit 
(Invitrogen, USA) and its content (A260) and purity (A260/ A280) was 
detected. Total RNA of 1 毺g was reverse transcribed into the first 
strand of cDNA and the product was PCR amplified after addition 
of 毬-catenin primers. 毬-catenin was used as the reference gene. 
Primer sequences were listed in Table 1. The amplification results 
were analyzed using the2-吟吟Ct method.
  PCR system (20 毺L): 2暳master 10 毺L, sense (10 毺M) and anti-
sense primers (10 毺M) 1 毺L respectively, cDNA 1 毺L, DEPC 
H2O 7 毺L. 
  PCR amplifying conditions: 95 曟 10 min; 95 曟 20 s, 60 曟 1 min 
(40 cycles); cooling at 4 曟.
  The protein levels of 毬-catenin and its downstream proteins (ie. 
Cyclin D1, c-Myc and TCF-1) were determined with Western-
blot analysis. Collected cells were lysed with RIPA lysis for 20 
min on ice and supernatants were collected after centrifugation for 
10 min at 4 曟 and 12 000 rpm. Protein extracts were separated by 
10% SDS polyacrylamide gel electrophoresis and then transferred 
onto a polyvinylidenefluoride (PVDF) membrane. After blocking 
with 5% non-fat milk, the blots were incubated with primary 
antibodies against 毬-catenin, CyclinD1, c-Myc, TCF-1 and 毬
-actin at 4 曟 overnight, followed by incubation with horseradish 
peroxidase-conjugated secondary antibody (1: 3 000) for 1 h at room 
temperature. The membrane was rinsed by TBST and color was 
developed in presence of chemoluminescent ECL-plus reagent. The 
intensity of protein fragments was quantified using Image-Pro Plus 
software.
2.8. sh毬-catenin effect 
  According to the method described in 2.2, HepG2 cells transfected 
with sh毬-catenin, named Lv-shRNA 毬-catenin-HepG2, were 
established to evaluate their cell proliferation capability (see 2.4) and 
毬-catenin protein levels (see 2.6).
  The primer sequence of target gene (sh毬-catenin) was listed in 
Table 1. All reaction systems and conditions were listed as following:
  PCR system (20 毺L): 10暳buffer 2 毺L, sense (10 毺M) and anti-
sense primers (10 毺M) 1 毺L respectively, ddH2O 16 毺L.
  PCR amplifying conditions: 95 曟 10 min; 75 曟 10 min, 55 曟 10 
min, 35 曟 10 min, 15 曟 10 min.
  Enzyme digestion system (20 毺L): 10暳buffer 2 毺L, Kpn I 
(10 U/毺L) and BamH I (10 U/毺L) 1 毺L respectively, DNA (500 
ng/毺L) 8 毺L, ddH2O 8 毺L, 37 曟 4 h.
  Connection system (10 毺L): vectors 1 毺L, target genes 7 毺L, 10
暳T4 buffer 1 毺L, T4DNA ligase 1 毺L, 16 曟 overnight.
2.9. Over expressing 毬-catenin effect
  According to the method described in 2.2, HepG2 cells over 
expressing 毬-catenin, named Lv-毬-catenin-HepG2, were 
established to evaluate their cell proliferation capability (see 2.4) and 
毬-catenin protein levels (see 2.6).
  The primer sequence of target gene (CTNNB 1) was listed in Table 
1. All reaction systems and conditions were listed as following:
  PCR system (50 毺L): 10暳buffer 5 毺L, sense (10 毺M) and 
anti-sense primers (10 毺M) 1 毺L respectively, CTNNB1 plasmid 
(100 ng/毺L) 1毺L, dNTPs (10 mM) 5 毺L, Pfu polymerase 1 毺L,
ddH2O 36 毺L. PCR amplifying conditions: 94 曟 5 min;  95 曟 30 s,
58 曟 30 s, 68 曟 2 min 30 s (30 cycles); 68 曟 5 min.
  Enzyme digestion system (23 毺L): 10暳buffer 4 毺L, Xba I
(10 U/毺L) and BamH I (10 U/毺L) 1 毺L respectively, DNA (500 
ng/毺L) 8 毺L, ddH2O 9 毺L, 37 曟 4 h.
  Connection system was similar to that in 2.8.
Table 1 
Primers sequence in this experiment.
Primers Sequence
pre-miR-214 F 5’- ATAGAATTCTTTCTCCCTTTCCCCTTACTCT
CC-3’
R 5’- CCAGGATCCTTTCATAGGCACCACTCACTT
TAC-3’
毬-catenin F 5’-AAAATGGCAGTGCGTTTAG-3’
R 5’-TTTGAAGGCAGTCTGTCGTA-3’
毬-actin F 5’-CTCCATCCTGGCCTCGCTGT-3’
R 5’-GCTGTCACCTTCACCGTTCC-3’
shRNA 毬-catenin F 5’-TTGTTATCAGAGGACTAAATA-3’
R 5’-TATTTAGTCCTCTGATAACAA-3’
CTNNB 1 F 5’-CGCTCTAGAATGGCTACTCAAGCTGATTTG
ATGG-3’
R 5’-CCAGGATCCTTACAGGTCAGTATCAAACCA
GGCC-3’
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2.10. Statistical analysis
  Data in the present study were analyzed with SPSS 13.0 software 
and expressed as mean±SD. Differences between groups were 
determined using Student’s t-test. P-values<0.05 were considered 
statistically significant for all variance tests. 
3. Results
3.1. Effects of miR-214 on HCC cell growth
  Figure 1 showed the cell growth of Lv-miR-214-HepG2, Lv-
control-HepG2 and HepG2 over the 5 days of culture. Ectopic 
expression of miR-214 reduced cell growth compared to the negative 
and blank control groups, being significantly different after 72 h 
(P<0.05).
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Figure 1. Effect of miR-214 on the growth of HCC cells.
Note: “*” indicates a significant difference compared to blank control 
(P<0.05), while “**” indicates an extremely significant difference (P<0.01).
3.2.  Effects of miR-214 on HCC cell proliferation
  The cell proliferation of cell lines (ie. Lv-miR-214-HepG2, Lv-
control-HepG2 and HepG2) was recorded in Figure 2. Ectopic 
expression of miR-214 inhibited cell proliferation by 21.7%, 38.8% 
and 49.7% at 48, 72 and 96 h respectively, which was statistically 
different to that of the negative and blank control group (P<0.05).
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Figure 2. Effect of miR-214 on the proliferation of HCC cells.
Note: “*” indicates a significant difference compared to blank control 
(P<0.05), while “**” indicates an extremely significant difference (P<0.01).
3.3. Effects of miR-214 on HCC cell colony forming ability
  The colonies in HCC cells with ectopic expression of miR-214 
were smaller in size and fewer compared to the control group 
(Figure 3). The effects on cell colony forming efficiency were less 
pronounced in cells transduced with miR-214 [(23.28±3.26)]% than 
in control cells [(51.31±3.97)%] (P=0.021).
  
Lv-control                                                   Lv-miR-214
Figure 3. Effect of miR-214 on the colony formation of HCC cells.
Table 2 
Effect of miR-214 on the colony forming efficiency of HCC cells.
Lv-miR-214 Lv-control t P
Colony number 46.00±5.23 125.00±11.80 - -
colony forming efficiency (%) 23.28±3.26   51.31±3.97 12.351 0.021
3.4. Effects of miR-214 on HCC cell cycles
  The rate of cells at G0/G1, S and G2 phase were shown in Figure 
4. Cells transduced with miR-214 were significantly higher in 
the G0/G1 phase fraction [(70.72±3.12)%] than the control group 
[(54.61±2.10)%] (P<0.05), but lower in the S phase fraction 
[(18.63±2.90)%] than the control group [(35.26±3.35)%] (P<0.05). 
No significant difference was observed in G2 phase fraction between 
cells with or without ectopic expression of miR-214 (P>0.05).
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Figure 4. Effect of miR-214 on HCC cell cycles. 
There is a significant difference in G0/G1 phase and S phase between 
experimental and control group (t is 7.92 and 8.56 respectively, and P=0.000). 
“**” indicates an extremely significant difference (P<0.01).
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3.5. Effects of miR-214 on 毬-catenin pathway
  RT-PCR results showed that there was a reduction in the 毬-catenin 
mRNA expression in cells transduced with miR-214 compared to the 
control cells (Figure 5), while no significant difference was recorded 
(P>0.05). According to Western-blot results, ectopic expression of 
miR-214 reduced the protein level of 毬-catenin and its downstream 
proteins Cyclin D1, c-Myc and TCF-1 compared to the control group 
(Figure 6).
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Figure 5. Effect of miR-214 on the 毬-catenin mRNA expression of HCC 
cells.
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Figure 6. Effect of miR-214 on the protein expression level of 毬-catenin and 
its downstream proteins. 
3.6. Effects of RNA interference and restoring 毬-catenin 
expression on cell proliferation and 毬-catenin expression
  Figure 7 showed the effects of RNA interference and restoring 
毬-catenin expression on HCC cell proliferation. No significant 
difference was observed in the cell proliferation between cells treated 
with miR-214 and those treated with shRNA 毬-catenin (P>0.05), 
while both of them were significantly lower than the control cells 
and cells over expressing 毬-catenin (P<0.05).
  Figure 8 showed the effects of RNA interference and restoring 毬
-catenin expression on the protein level of 毬-catenin. Western-blot 
results showed a similar 毬-catenin protein level of cells transduced 
with shRNA 毬-catenin to that transduced with miR-214 and both of 
them were lower compared to the control group. A higher 毬-catenin 
protein level was observed in cells over expressing 毬-catenin than 
in control cells.
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Figure 7. Effect of 毬-catenin RNA interference and overexpression on HCC 
proliferation. 
There is a significant difference between the treatments of Lv-miR-214 
and Lv-shRNA 毬-catenin and control (t is 0.352 and 0.398 respectively, 
P=0.000). “**” indicates an extremely significant difference (P<0.01).
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Figure 8. Effect of 毬-catenin RNA interference and overexpression on the 
protein level of 毬-catenin of HCC.
 a, b, c and d means Lv-control, Lv-miR-214, Lv-shRNA 毬-catenin and Lv-
毬-catenin, respectively.
4. Discussion
  HCC is one of the fatal cancers in clinical practice and studies on 
its pathogenesis have long been the focus for researchers at home 
and abroad to improve treatment technology for this disease. In past 
decades, the miRNA discovery opened a new door to the cancer 
therapy and many miRNA-related treatment methods developed. 
These small noncoding RNAs bind to the 3’ untranslated region 
(UTR) or the open reading frame (ORF) of the target mRNA, 
resulting in the degradation of target mRNA and therefore a 
translational repression[1,10]. The miRNA has been pathologically 
proved to be a new target of drug action during cancer onset and 
progression[10,11]. Due to this potential value, miRNA has been 
used as a marker of cancer diagnosis and prognosis. In the present 
study, the effect of miR-214 on HCC was explored according to the 
cell growth, proliferation, colony forming ability and cell cycles 
determind in cells transduced with miR-214. At the same time, 
the expression of 毬-catenin and its downstream proteins in cells 
transduced with miR-214 was determined and compared with that 
in cells treated with RNA interference and restoring 毬-catenin 
expression to elucidate the mechanism of miR-214 influencing HCC 
by targeting 毬-catenin pathway.
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4.1. Effects of miR-214 on HCC cell growth, proliferation, 
colony forming ability and cell cycles
  miR-214 is reported to have a significant role in tumor inhibition. 
For example, the expression of miR-214 can promote apoptosis 
and reduce cell growth, proliferation, migration and invasion etc. 
in cancers such as gastric carcinoma, cervical carcinoma and 
nasopharyngeal carcinoma[12-14]. In the present study, we ectopically 
expressed miR-214 in HepG2 cells and a significant reduction in 
cell growth after culture of 48-72 h and colony forming ability was 
obtained. Meanwhile, treatment of miR-214 resulted in an increase 
in the G0/G1 phase fraction, but a decrease in S phase fraction. 
This indicates that miR-214 expression makes cancer cells arrest 
in G0/G1 phase and inhibits their proliferation by interfering with 
their progress through to the S phase where DNA is synthesized. 
Similarly, other miRNAs such as miR-7 and miR-126 are also 
reported to arrest cells in G0/G1 phase[15,16]. Thus, the inhibitory 
effect of miR-214 on HCC cells is confirmed and its abnormal 
variation is expected to significantly affect the development of HCC. 
However, the expression of miR-214 is tumor-specific. As reported, 
miR-214 was up-regulated in pancreatic carcinoma, leading to the 
poor response of pancreatic cancer cells to chemotherapy[17]. For 
gastric carcinoma, the up-regulation of miR-214 expression could 
promote the cancer cell proliferation and migration, which may be 
related with its negative role in regulation of PTEN protein[12]. While 
in HCC[8,18], ovarian carcinoma[19] and cervical carcinoma[13], miR-
214 expression was up-regulated. In addition to miR-214, many 
other miRNAs contribute to the HCC onset and progression and 
they showed different expression patterns: there is a down-regulation 
in the expression of some miRNAs such as miR-30a, miR-125b 
and miR-185[20-22], but an up-regulation in the expression of other 
miRNAs such as miR-224, miR-517a and miR-520c[22-24].
4.2. Mechanism of miR-214 inhibiting HCC development by 
targeting 毬-catenin pathway
  毬-catenin is reported to be significant for the development of 
cancers such as adrenal carcinoma[25], colorectal carcinoma[26] 
and gastroenteric carcinomas[27] because this gene silence can 
activate apoptosis and consequently inhibit cancer cell proliferation. 
According to results in the present study, the protein level of
毬-catenin was significantly inhibited by miR-214, while its mRNA 
level showed no significant difference compared to the negative 
control group. This suggested that miR-214 mainly affect the 
expression of 毬-catenin on the level of translation. For HCC, the 
Wnt/毬-catenin signaling pathway is an important biomarker due 
to its comprehensive function in cell differentiation, proliferation, 
and maintenance of homeostasis[28,29]. As deregulation of the 
Wnt pathway can affect the expression of target genes including 
Cyclin D1 and c-Myc[28], it is considered as an early event in 
hepatocarcinogenesis[30]. We determined the protein level of
毬-catenin and its downstream proteins (ie. Cyclin D1, c-Myc and 
TCF-1) with Western-blot method and confirmed the inhibitory 
effect of miR-214 on the expression of downstream proteins in the 
毬-catenin pathway. Nevertheless, our experiment results showed 
that the inhibited HCC cell proliferation and 毬-catenin expression 
could recover due to the restoring 毬-catenin expression. Therefore, 
miR-214 is suggested to play an inhibit role in the 毬-catenin 
pathway, consequently reducing HCC cell proliferation.
  This study demonstrates that miR-214 is a suppressor for the 
development of HCC. This can provide a better understanding 
of the mechanism of HCC onset and progression, and may also 
used as a reference for HCC therapy. Previous reports have shown 
that the function of miR-214 in tumor suppression is correlated 
with its inhibition on 毬-catenin. However, it must be taken into 
consideration that the type and number of target gene or pathway 
of miR-214 is tumor-specific. In cervical carcinoma, miR-214 
can negatively regulate the expression of Bcl212, though this 
situation can partially be reversed by over-expression of Bcl2l2[13]. 
In myeloma, miR-214 is associated with the up-regulation of p53 
expression and the down-regulation of PSMD10 expression with 
the latter encoding the oncoprotein gankyrin[31]. While the restoring 
expression of Leucine zipper putative tumor suppressor 1 can 
reverse the promotion effect of up-regulated miR-214 expression on 
osteosarcoma cell proliferation[32]. Thus, a further study is needed to 
elucidate the effect of miR-214 on other target genes and pathways, 
and the synergistic effect of target genes and pathways on HCC 
onset and progression.
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